The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases

Objectives: Sorafenib is the only FDA-approved first-line target drug for HCC patients. However, sorafenib merely confers 3-5 months of survival benefit with less than 30% of HCC patients sensitive to sorafenib therapy. Thus, it's necessary to develop a sensitizer for hepatocellular carcinoma (...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Guifang, Shi, Zhaopeng, Shangguan, Chengfang, Zhang, Jieying, Yuan, Yuan, Chen, Lei, Liu, Weiren, Li, Biao, Meng, Songshu, Xiong, Wujun, Mi, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058709/
https://www.ncbi.nlm.nih.gov/pubmed/33897895
http://dx.doi.org/10.7150/thno.59841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058709/
https://www.ncbi.nlm.nih.gov/pubmed/33897895
http://dx.doi.org/10.7150/thno.59841

Ejemplares similares